Sandra Gafner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sandra Gafner has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Beat Mueller
Medical Faculty Department of Clinical Research, University of Basel, Basel, Switzerland; Medical University Department, Clinic for Endocrinology, Diabetes and Metabolism, Cantonal Hospital Aarau, Switzerland
2 shared publications - Philipp Schuetz
Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland
2 shared publications - Tristan Struja
Department of Internal Medicine, Medical University Clinic, Cantonal Hospital Aarau, Aarau, Switzerland; Laboratory for Computational Physiology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA; Internal Medicine Clinic, Hospital Muri, Muri, Switzerland
2 shared publications - Alexander Kutz
Division of General Internal and Emergency Medicine, University Department of Medicine, Kantonsspital Aarau, Aarau, Switzerland
1 shared publication - Ciril Baechli
Department of General Internal Medicine, Medical University Clinic, Aarau, Switzerland
1 shared publication - Claudine Angela Blum
Endocrinology, Diabetology and Metabolism, Department of Internal Medicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland
1 shared publication
Latest Publications
- 27 March 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (4) , 441-453
Incidence and hospital outcomes of acute adrenal crisis in a Swiss-wide cohort study
Background: Adrenal crises (AC) are life-threatening emergencies for which epidemiological data remain scarce, particularly in older adults. We analyzed nationwide data on AC-related hospitalizations in Switzerland between 2012 and 2022 to determine incidence, clinical outcomes, and predictors of adverse events, emphasizing differences across age groups and etiologies of adrenal insufficiency. Methods: We conducted a nationwide retrospective cohort study using hospital discharge data linked to the national death registry. The primary outcome was the incidence of AC hospitalizations; secondary outcomes were a composite endpoint of in-hospital mortality, intensive care unit (ICU) admission, and 30-day rehospitalization. We also assessed 1-year mortality and duration of hospital and ICU stay. Results: We identified 2302 AC-related hospitalizations with incidence increasing over time, peaking in patients >80 years, with the steepest rise in those with central adrenal insufficiency. Compared with matched controls, AC was associated with higher odds of the secondary composite outcome (IRR 1.60; 95% confidence interval [CI] 1.48-1.73), primarily driven by ICU admissions (IRR 1.99; 95% CI 1.8-2.21). Patients with unspecified etiology of adrenal insufficiency had the highest odds for in-hospital mortality (IRR 1.8; 95% CI 1.48-2.19) and 1-year all-cause mortality (IRR 1.41; 95% CI 1.23-1.62). Key predictors of adverse outcomes included unspecified etiology of adrenal insufficiency, advanced age, male sex, arginine vasopressin deficiency, sepsis, and cancer. Conclusion: In Switzerland, AC-related hospitalizations have increased over the past decade, primarily driven by an increase in central adrenal insufficiency, likely linked to expanding glucocorticoid and immunotherapy use. Older adults remain disproportionately vulnerable to adverse outcomes.
- 27 March 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (4) , 441-453
Incidence and hospital outcomes of acute adrenal crisis in a Swiss-wide cohort study
Background: Adrenal crises (AC) are life-threatening emergencies for which epidemiological data remain scarce, particularly in older adults. We analyzed nationwide data on AC-related hospitalizations in Switzerland between 2012 and 2022 to determine incidence, clinical outcomes, and predictors of adverse events, emphasizing differences across age groups and etiologies of adrenal insufficiency. Methods: We conducted a nationwide retrospective cohort study using hospital discharge data linked to the national death registry. The primary outcome was the incidence of AC hospitalizations; secondary outcomes were a composite endpoint of in-hospital mortality, intensive care unit (ICU) admission, and 30-day rehospitalization. We also assessed 1-year mortality and duration of hospital and ICU stay. Results: We identified 2302 AC-related hospitalizations with incidence increasing over time, peaking in patients >80 years, with the steepest rise in those with central adrenal insufficiency. Compared with matched controls, AC was associated with higher odds of the secondary composite outcome (IRR 1.60; 95% confidence interval [CI] 1.48-1.73), primarily driven by ICU admissions (IRR 1.99; 95% CI 1.8-2.21). Patients with unspecified etiology of adrenal insufficiency had the highest odds for in-hospital mortality (IRR 1.8; 95% CI 1.48-2.19) and 1-year all-cause mortality (IRR 1.41; 95% CI 1.23-1.62). Key predictors of adverse outcomes included unspecified etiology of adrenal insufficiency, advanced age, male sex, arginine vasopressin deficiency, sepsis, and cancer. Conclusion: In Switzerland, AC-related hospitalizations have increased over the past decade, primarily driven by an increase in central adrenal insufficiency, likely linked to expanding glucocorticoid and immunotherapy use. Older adults remain disproportionately vulnerable to adverse outcomes.
- Open Access
- 17 December 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (12) , 4079
Outcomes of Hospitalized Patients with Glucocorticoid-Induced Hyperglycemia—A Retrospective Analysis
Background: Glucocorticoid (GC)-induced hyperglycemia is a frequent side effect in hospitalized patients. Guidelines recommend treat-to-target treatment between 6–10 mmol/L (108–180 mg/dL) with insulin, but data on outcome is scarce. We investigated the 30-day outcome in hospitalized patients receiving GCs. Methods: All patient records of hospitalized patients between January 2014 and April 2018 were screened for GC administration and consecutive hyperglycemia. The primary combined endpoint consisted of death, cardiovascular events, and infections until 30 days after admission. Hypoglycemia was a secondary outcome. Results: Of the 2424 hospitalized patients (9.6% of all hospitalized patients) who received systemic GCs and met inclusion criteria, the overall incidence for GC-induced hyperglycemia was 812 (33.5%), and 89 (3.7%) had at least one documented hypoglycemia during their hospital stay. Compared to patients with normoglycemia, GC-induced hyperglycemia had an adjusted-odds ratio of 1.68 (95% CI 1.25–2.26) for the combined primary endpoint. Hypoglycemia even had an odds ratio of 1.95 (95% CI 1.2–3.17). Conclusions: Mortality, cardiovascular events, and rate of infections were markedly higher in patients with GC-induced hyperglycemia as compared to patients with normoglycemia. Importantly, hypoglycemia was associated with a doubled risk for adverse outcome. Future studies should evaluate whether optimized glucose control by minimizing the risk for hypoglycemia has a beneficial effect on clinical outcomes in patients with GC-induced hyperglycemia.
- 17 December 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (12) , 4079
Open AccessOutcomes of Hospitalized Patients with Glucocorticoid-Induced Hyperglycemia—A Retrospective Analysis
Background: Glucocorticoid (GC)-induced hyperglycemia is a frequent side effect in hospitalized patients. Guidelines recommend treat-to-target treatment between 6–10 mmol/L (108–180 mg/dL) with insulin, but data on outcome is scarce. We investigated the 30-day outcome in hospitalized patients receiving GCs. Methods: All patient records of hospitalized patients between January 2014 and April 2018 were screened for GC administration and consecutive hyperglycemia. The primary combined endpoint consisted of death, cardiovascular events, and infections until 30 days after admission. Hypoglycemia was a secondary outcome. Results: Of the 2424 hospitalized patients (9.6% of all hospitalized patients) who received systemic GCs and met inclusion criteria, the overall incidence for GC-induced hyperglycemia was 812 (33.5%), and 89 (3.7%) had at least one documented hypoglycemia during their hospital stay. Compared to patients with normoglycemia, GC-induced hyperglycemia had an adjusted-odds ratio of 1.68 (95% CI 1.25–2.26) for the combined primary endpoint. Hypoglycemia even had an odds ratio of 1.95 (95% CI 1.2–3.17). Conclusions: Mortality, cardiovascular events, and rate of infections were markedly higher in patients with GC-induced hyperglycemia as compared to patients with normoglycemia. Importantly, hypoglycemia was associated with a doubled risk for adverse outcome. Future studies should evaluate whether optimized glucose control by minimizing the risk for hypoglycemia has a beneficial effect on clinical outcomes in patients with GC-induced hyperglycemia.